Literature DB >> 10364342

A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans.

X Lu1, T M Tumpey, T Morken, S R Zaki, N J Cox, J M Katz.   

Abstract

During 1997 in Hong Kong, 18 human cases of respiratory illness, including 6 fatalities, were caused by highly pathogenic avian influenza A (H5N1) viruses. Since H5 viruses had previously been isolated only from avian species, the outbreak raised questions about the ability of these viruses to cause severe disease and death in humans. To better understand the pathogenesis and immunity to these viruses, we have used the BALB/c mouse model. Four H5N1 viruses replicated equally well in the lungs of mice without prior adaptation but differed in lethality for mice. H5N1 viruses that were highly lethal for mice were detected in multiple organs, including the brain. This is the first demonstration of an influenza A virus that replicates systemically in a mammalian species and is neurotropic without prior adaptation. The mouse model was also used to evaluate a strategy of vaccination against the highly pathogenic avian H5N1 viruses, using an inactivated vaccine prepared from nonpathogenic A/Duck/Singapore-Q/F119-3/97 (H5N3) virus that was antigenically related to the human H5N1 viruses. Mice administered vaccine intramuscularly, with or without alum, were completely protected from lethal challenge with H5N1 virus. Protection from infection was also observed in 70% of animals administered vaccine alone and 100% of mice administered vaccine with alum. The protective effect of vaccination correlated with the level of virus-specific serum antibody. These results suggests a strategy of vaccine preparedness for rapid intervention in future influenza pandemics that uses antigenically related nonpathogenic viruses as vaccine candidates.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10364342      PMCID: PMC112651     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  25 in total

1.  Induction of partial immunity to influenza by a neuraminidase-specific vaccine.

Authors:  R B Couch; J A Kasel; J L Gerin; J L Schulman; E D Kilbourne
Journal:  J Infect Dis       Date:  1974-04       Impact factor: 5.226

2.  Antibody response in humans to influenza virus type B host-cell-derived variants after vaccination with standard (egg-derived) vaccine or natural infection.

Authors:  M W Harmon; P A Rota; H H Walls; A P Kendal
Journal:  J Clin Microbiol       Date:  1988-02       Impact factor: 5.948

3.  Characterization of virulent and avirulent A/chicken/Pennsylvania/83 influenza A viruses: potential role of defective interfering RNAs in nature.

Authors:  W J Bean; Y Kawaoka; J M Wood; J E Pearson; R G Webster
Journal:  J Virol       Date:  1985-04       Impact factor: 5.103

4.  DNA vaccine encoding hemagglutinin provides protective immunity against H5N1 influenza virus infection in mice.

Authors:  S Kodihalli; H Goto; D L Kobasa; S Krauss; Y Kawaoka; R G Webster
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

5.  Genetic stability of A/Ann Arbor/6/60 cold-mutant (temperature-sensitive) live influenza virus genes: analysis by oligonucleotide mapping of recombinant vaccine strains before and after replication in volunteers.

Authors:  N J Cox; A P Kendal
Journal:  J Infect Dis       Date:  1984-02       Impact factor: 5.226

6.  Recombinant neuraminidase vaccine protects against lethal influenza.

Authors:  T Deroo; W M Jou; W Fiers
Journal:  Vaccine       Date:  1996-04       Impact factor: 3.641

7.  Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults.

Authors:  D C Powers; G E Smith; E L Anderson; D J Kennedy; C S Hackett; B E Wilkinson; F Volvovitz; R B Belshe; J J Treanor
Journal:  J Infect Dis       Date:  1995-06       Impact factor: 5.226

8.  Survey of the hemagglutinin (HA) cleavage site sequence of H5 and H7 avian influenza viruses: amino acid sequence at the HA cleavage site as a marker of pathogenicity potential.

Authors:  D A Senne; B Panigrahy; Y Kawaoka; J E Pearson; J Süss; M Lipkind; H Kida; R G Webster
Journal:  Avian Dis       Date:  1996 Apr-Jun       Impact factor: 1.577

9.  Hantavirus pulmonary syndrome. Pathogenesis of an emerging infectious disease.

Authors:  S R Zaki; P W Greer; L M Coffield; C S Goldsmith; K B Nolte; K Foucar; R M Feddersen; R E Zumwalt; G L Miller; A S Khan
Journal:  Am J Pathol       Date:  1995-03       Impact factor: 4.307

10.  Human CD4+ T-cell repertoire of responses to influenza A virus hemagglutinin after recent natural infection.

Authors:  C M Gelder; K I Welsh; A Faith; J R Lamb; B A Askonas
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

View more
  175 in total

1.  The PB2 subunit of the influenza virus RNA polymerase affects virulence by interacting with the mitochondrial antiviral signaling protein and inhibiting expression of beta interferon.

Authors:  Katy M Graef; Frank T Vreede; Yuk-Fai Lau; Amber W McCall; Simon M Carr; Kanta Subbarao; Ervin Fodor
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

2.  Human pulmonary microvascular endothelial cells support productive replication of highly pathogenic avian influenza viruses: possible involvement in the pathogenesis of human H5N1 virus infection.

Authors:  Hui Zeng; Claudia Pappas; Jessica A Belser; Katherine V Houser; Weiming Zhong; Debra A Wadford; Troy Stevens; Ron Balczon; Jacqueline M Katz; Terrence M Tumpey
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

Review 3.  The contribution of animal models to the understanding of the host range and virulence of influenza A viruses.

Authors:  Christopher D O'Donnell; Kanta Subbarao
Journal:  Microbes Infect       Date:  2011-01-27       Impact factor: 2.700

Review 4.  Immunity to influenza: the challenges of protecting an aging population.

Authors:  Jacqueline M Katz; Julie Plowden; Mary Renshaw-Hoelscher; Xiuhua Lu; Terrence M Tumpey; Suryaprakash Sambhara
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 5.  Influenza: emergence and control.

Authors:  Aleksandr S Lipatov; Elena A Govorkova; Richard J Webby; Hiroichi Ozaki; Malik Peiris; Yi Guan; Leo Poon; Robert G Webster
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

6.  Critical role of airway macrophages in modulating disease severity during influenza virus infection of mice.

Authors:  Michelle D Tate; Danielle L Pickett; Nico van Rooijen; Andrew G Brooks; Patrick C Reading
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

7.  Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus.

Authors:  Joshua M DiNapoli; Lijuan Yang; Amorsolo Suguitan; Subbiah Elankumaran; David W Dorward; Brian R Murphy; Siba K Samal; Peter L Collins; Alexander Bukreyev
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

8.  Naturally occurring mutations in the PA gene are key contributors to increased virulence of pandemic H1N1/09 influenza virus in mice.

Authors:  Yipeng Sun; Qi Xu; Ye Shen; Linqing Liu; Kai Wei; Honglei Sun; Juan Pu; Kin-Chow Chang; Jinhua Liu
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

9.  Early control of H5N1 influenza virus replication by the type I interferon response in mice.

Authors:  Kristy J Szretter; Shivaprakash Gangappa; Jessica A Belser; Hui Zeng; Hualan Chen; Yumiko Matsuoka; Suryaprakash Sambhara; David E Swayne; Terrence M Tumpey; Jacqueline M Katz
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

10.  Pathogenesis of 1918 pandemic and H5N1 influenza virus infections in a guinea pig model: antiviral potential of exogenous alpha interferon to reduce virus shedding.

Authors:  Neal Van Hoeven; Jessica A Belser; Kristy J Szretter; Hui Zeng; Peter Staeheli; David E Swayne; Jacqueline M Katz; Terrence M Tumpey
Journal:  J Virol       Date:  2009-01-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.